Format

Send to

Choose Destination
J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):41-46. doi: 10.4274/jtgga.galenos.2018.2018.0039. Epub 2018 Jun 19.

Role of erythropoietin and its receptor in the development of endometriosis in rats

Author information

1
Department of Physiology, Alanya Alaaddin Keykubat University School of Medicine, Antalya, Turkey
2
Regenerative and Restorative Medical Research Center (REMER), İstanbul Medipol University, İstanbul, Turkey
3
Department of Physiology, İstanbul Medipol University School of Medicine, İstanbul, Turkey
4
Department of Medical Biology, University of Health Sciences School of Medicine, İstanbul, Turkey
5
Department of Histology and Embryology, İstanbul Medipol University School of Medicine, İstanbul, Turkey
6
Experimental Animal Center, İstanbul Medipol University, İstanbul, Turkey
7
Department of Pharmaceutical Technology, Yeditepe University School of Pharmacy, İstanbul, Turkey
8
Department of Nephrology, Yeditepe University School of Medicine, İstanbul, Turkey
9
Department of General Surgery, İstanbul Medipol University School of Medicine, İstanbul, Turkey

Abstract

Objective:

Besides its hematopoietic function, erythropoietin (EPO) may protect tissues from degenerative disorders. As such, EPO and its receptors were revealed in nonhematopoietic cells, including stromal and endometrial epithelial cells. However, the role of EPO in endometrial disorders is still unknown. Here, we aimed to examine the role of EPO and its receptor activation in the development of endometriosis in rats.

Material and Methods:

Animals were treated with EPO, darbepoietin (the synthetic form of EPO) or EPO’s receptor activator, methoxy polyethylene glycol-epoetin beta (MIRCERA), after development of endometriosis. Endometriosis was induced by estrogen-administration following surgical attachment of endometrial surface on the inner abdominal wall. Treatments were started 3 weeks after induction of endometriosis and continued for the following 3 weeks. For the analysis of recurrence of endometriosis, additional analyses were conducted 3 weeks after cessation of treatments.

Results:

As compared with vehicle-treated animals, lesion size was reduced significantly and recurrence of endometriosis was not observed in all treatment groups. Histopathologic examination revealed that EPO and darbepoietin were more effective than MIRCERA- and vehicle-treated animals.

Conclusion:

Here we provide evidence that EPO is a promising candidate for the treatment of endometriosis. Our histopathologic results in particular indicate that EPO is more effective than its receptor activator MIRCERA in the development endometriosis.

KEYWORDS:

Endometriosis; darbepoietin; erythropoietin; receptor activator; MIRCERA

Free full text

Supplemental Content

Full text links

Icon for Galenos Yayinevi
Loading ...
Support Center